Serina Therapeutics Secures $5 Million Funding for SER-252
Serina Therapeutics, a leading clinical-stage biotechnology firm, recently announced that it has successfully drawn down the initial $5 million from a financing agreement that can provide up to $20 million. This funding is specifically earmarked to propel Serina’s planned registrational trial of SER-252 in the management of advanced Parkinson’s disease.
Advancing Registrational Trial Initiatives
Under the terms of the financing agreement, the funds will be utilized to advance the company’s clinical strategies, especially for SER-252. This investigational therapy represents a significant step forward for treating individuals dealing with the complexities of advanced Parkinson’s disease.
Details of the Financing Agreement
This initial $5 million tranche serves as part of a larger financial strategy tied to specific development milestones, including goals related to patient enrollment in the upcoming clinical trial. Serina is poised to maximize this capital effectively as it seeks to address the unmet needs of this patient population.
Strategic Approach to Parkinson’s Treatment
“This financing milestone enables us to push forward with SER-252 into the registrational trial phase, bringing us closer to fulfilling the needs of those living with advanced Parkinson’s disease,” remarked Steve Ledger, the Chief Executive Officer at Serina Therapeutics. With the crucial IND submission to the FDA completed, the company is now focusing on timely study initiation.
Investigational New Drug Application
Serina has submitted an Investigational New Drug (IND) application to the U.S. FDA and has successfully secured Ethical approval from the Human Research Ethics Committee (HREC) in Australia. This pivotal step shows Serina’s commitment to start its registrational study, with plans to commence patient dosing before the end of the current year.
Overview of the SER-252 Study Design
The SER-252-1b study is designed as a randomized, double-blind, placebo-controlled Phase 1b trial. This innovative approach includes both single-ascending-dose and multiple-ascending-dose components, engaging adults with Parkinson’s disease who experience motor fluctuations. The trial aims to provide critical data on safety, tolerability, and pharmacokinetics of SER-252 compared to placebo, alongside exploratory efficacy measures.
About SER-252 Therapy
SER-252 is an investigative therapy that utilizes Serina’s proprietary POZ platform. This treatment is tailored to offer continuous dopaminergic stimulation (CDS) via a convenient subcutaneous injection, which aims to alleviate symptoms of motor fluctuations often faced by advanced Parkinson’s patients. With strategic partnerships enhancing its delivery capabilities, SER-252 seeks to improve patient lives dramatically.
Understanding Serina Therapeutics
Serina Therapeutics is dedicated to developing a diverse range of drug candidates aimed at treating neurological diseases among other indications. With their advanced POZ platform, the company is committed to improving treatment portfolios while focusing on enhanced efficacy and safety across various forms of therapy.
Frequently Asked Questions
What is the recent funding amount raised by Serina Therapeutics?
Serina Therapeutics has secured a $5 million tranche, part of a larger $20 million financing agreement to support its clinical trials.
What is SER-252 being developed for?
SER-252 is being developed as a treatment for advanced Parkinson's disease, focusing on addressing motor fluctuations in patients.
What are the phases of the SER-252 trial?
The SER-252-1b trial is a randomized, double-blind, placebo-controlled Phase 1b study designed to assess safety and efficacy.
Where is Serina Therapeutics headquartered?
Serina Therapeutics is headquartered in Huntsville, Alabama, situated on the HudsonAlpha Institute of Biotechnology campus.
How can I contact Serina Therapeutics for inquiries?
For inquiries, interested parties can contact Stefan Riley at sriley@serinatherapeutics.com or by calling (256) 327-9630.
